Pediatric Oncology Pioneer Wendy B. London to Give Talk at Lindsey Wilson College
Community is invited to this free public lecture.
A pioneer in pediatric oncology with more than 20 years of experience in the design, conduct, analysis and reporting of clinical cancer trials will speak at Lindsey Wilson College on Monday, September 24 at 2 p.m. CT in the Norma and Glen Hodge Center for Discipleship, 402 Helen Flatt Drive. The talk is free and open to the public.
Wendy B. London, Ph.D., whose talk is titled “Clinical Cancer Research: Examples From Pediatric Oncology," hopes to catch the interest of students by using examples from real clinical trials.
"Cancer research is more than just laboratory experiments to find or create new drugs,” said Dr. London. “Pediatric cancer clinical trials are carefully controlled experiments in children, conducted with the informed consent of the parents and, for older children, assent of the child.”
Dr. London will present examples of clinical trials developed to identify new therapies to improve the outcome of children with neuroblastoma. Students will see how unsuccessful trials are as useful as successful trials.
“What an incredible opportunity to expose this community and our students to one of the world’s leading researchers fighting every day to find a cure for cancer," said LWC President William T. Luckey Jr. “Dr. Wendy London is one of our dearest personal friends and Elise and I were so touched that she offered to come to Lindsey Wilson College to share her expertise. She is brilliant, engaging and I’m sure will be an excellent speaker.”
Dr. London’s primary research interests include neuroblastoma, prognostic stratification and design of clinical trials. She currently serves as the Director of the Clinical and Translational Investigation Program (CTIP) and the Director of the Biostatistics Program of the Division of Pediatric Hematology/Oncology at Boston Children’s Hospital and Dana-Farber Cancer Institute (BCH/DFCI), Harvard Medical School. Dr. London’s findings on the effect of age on neuroblastoma outcome resulted in a reduction of therapy for patients 12-18 months old. She has developed new methods for stratified Phase II designs, now widely used in multi-center trials for small, heterogeneous cohorts.
Dr. London received a Ph.D., in Biostatistics from Virginia Commonwealth University, She is a member of the American Statistical Association, International Society for Pediatric Oncology and American Society for Clinical Oncology. In 2006, Dr. London received the Audrey Evans Prize for Outstanding Paper in Clinical Research, Advances in Neuroblastoma Research Association.
For more information about this public lecture, contact Amy Thompson-Wells at thompsoa@lindsey.edu or call 270-384-8001.